Synergy scores were normalized using Min-Max Scaling to facilitate visual comparisons.
| DrugCom Name |
DrugCom ID |
Component Drug |
Indication |
REF |
|
ABIRATERONE + Pomalidomide
|
DCVK77Q
|
ABIRATERONE
|
Adult acute myeloid leukemia (Cell Line: HL-60(TB))
|
[3] |
|
ABIRATERONE + Pomalidomide
|
DC5B0TS
|
ABIRATERONE
|
Clear cell renal cell carcinoma (Cell Line: A498)
|
[3] |
|
ABIRATERONE + Pomalidomide
|
DC27L74
|
ABIRATERONE
|
Clear cell renal cell carcinoma (Cell Line: CAKI-1)
|
[3] |
|
ABIRATERONE + Pomalidomide
|
DC7XPEK
|
ABIRATERONE
|
Glioblastoma (Cell Line: SNB-75)
|
[3] |
|
ABIRATERONE + Pomalidomide
|
DCYWOTM
|
ABIRATERONE
|
Papillary renal cell carcinoma (Cell Line: ACHN)
|
[3] |
|
ABIRATERONE + Pomalidomide
|
DCMNEQS
|
ABIRATERONE
|
Renal cell carcinoma (Cell Line: UO-31)
|
[3] |
|
ABIRATERONE + Pomalidomide
|
DC2R0OY
|
ABIRATERONE
|
Cutaneous melanoma (Cell Line: SK-MEL-5)
|
[4] |
|
ABIRATERONE + Pomalidomide
|
DCY52QI
|
ABIRATERONE
|
Lung adenocarcinoma (Cell Line: EKVX)
|
[4] |
|
ABIRATERONE + Pomalidomide
|
DC3S7MU
|
ABIRATERONE
|
Non-small cell lung carcinoma (Cell Line: HOP-92)
|
[4] |
|
Acamprosate + Pomalidomide
|
DCOUKGB
|
Acamprosate
|
Chronic myelogenous leukemia (Cell Line: KBM-7)
|
[3] |
|
Anastrozole + Pomalidomide
|
DCPO570
|
Anastrozole
|
Adenocarcinoma (Cell Line: NCIH23)
|
[3] |
|
Anastrozole + Pomalidomide
|
DCUCWCT
|
Anastrozole
|
Adult acute myeloid leukemia (Cell Line: HL-60(TB))
|
[3] |
|
Anastrozole + Pomalidomide
|
DC44B5Z
|
Anastrozole
|
Astrocytoma (Cell Line: SNB-19)
|
[3] |
|
Anastrozole + Pomalidomide
|
DC7L87U
|
Anastrozole
|
Chronic myelogenous leukemia (Cell Line: K-562)
|
[3] |
|
Anastrozole + Pomalidomide
|
DCDFF63
|
Anastrozole
|
Cutaneous melanoma (Cell Line: SK-MEL-28)
|
[3] |
|
Anastrozole + Pomalidomide
|
DCW6G7W
|
Anastrozole
|
High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-5)
|
[3] |
|
Anastrozole + Pomalidomide
|
DCOBHUC
|
Anastrozole
|
Renal cell carcinoma (Cell Line: UO-31)
|
[3] |
|
Anastrozole + Pomalidomide
|
DCLP0TM
|
Anastrozole
|
Renal cell carcinoma (Cell Line: SN12C)
|
[3] |
|
Anastrozole + Pomalidomide
|
DC4ABE3
|
Anastrozole
|
Carcinoma (Cell Line: MCF7)
|
[5] |
|
Anastrozole + Pomalidomide
|
DCOM3MI
|
Anastrozole
|
Colon adenocarcinoma (Cell Line: COLO 205)
|
[5] |
|
Anastrozole + Pomalidomide
|
DC8KVYX
|
Anastrozole
|
Invasive ductal carcinoma (Cell Line: HS 578T)
|
[5] |
|
Anastrozole + Pomalidomide
|
DC8QLUO
|
Anastrozole
|
Invasive ductal carcinoma (Cell Line: BT-549)
|
[5] |
|
Anastrozole + Pomalidomide
|
DC5TSQG
|
Anastrozole
|
Invasive ductal carcinoma (Cell Line: T-47D)
|
[5] |
|
Arfolitixorin + Pomalidomide
|
DCK3IJ0
|
Arfolitixorin
|
Chronic myelogenous leukemia (Cell Line: KBM-7)
|
[3] |
|
Arfolitixorin + Pomalidomide
|
DCZNPY6
|
Arfolitixorin
|
Clear cell renal cell carcinoma (Cell Line: CAKI-1)
|
[3] |
|
Arfolitixorin + Pomalidomide
|
DCV1398
|
Arfolitixorin
|
Glioma (Cell Line: SF-295)
|
[3] |
|
Arfolitixorin + Pomalidomide
|
DCD8V0J
|
Arfolitixorin
|
Renal cell carcinoma (Cell Line: SN12C)
|
[3] |
|
Arfolitixorin + Pomalidomide
|
DC9E4GC
|
Arfolitixorin
|
Colon carcinoma (Cell Line: KM12)
|
[5] |
|
Arfolitixorin + Pomalidomide
|
DC4QYTR
|
Arfolitixorin
|
Adenocarcinoma (Cell Line: HCT116)
|
[4] |
|
Arfolitixorin + Pomalidomide
|
DCL9328
|
Arfolitixorin
|
Malignant melanoma (Cell Line: UACC62)
|
[4] |
|
Arfolitixorin + Pomalidomide
|
DC9Y6TL
|
Arfolitixorin
|
Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3)
|
[4] |
|
AS-1949490 + Pomalidomide
|
DC7084O
|
AS-1949490
|
Chronic myelogenous leukemia (Cell Line: KBM-7)
|
[3] |
|
Auranofin + Pomalidomide
|
DCZYYZS
|
Auranofin
|
Chronic myelogenous leukemia (Cell Line: KBM-7)
|
[3] |
|
Bendamustine hydrochloride + Pomalidomide
|
DCGI743
|
Bendamustine hydrochloride
|
Invasive ductal carcinoma (Cell Line: BT-549)
|
[5] |
|
Bendamustine hydrochloride + Pomalidomide
|
DC9TS0X
|
Bendamustine hydrochloride
|
Adenocarcinoma (Cell Line: A549)
|
[4] |
|
Bendamustine hydrochloride + Pomalidomide
|
DCVEOP8
|
Bendamustine hydrochloride
|
Melanoma (Cell Line: UACC-257)
|
[4] |
|
BIO-300 + Pomalidomide
|
DCA3HMM
|
BIO-300
|
Glioma (Cell Line: SF-295)
|
[3] |
|
Bleomycin + Pomalidomide
|
DCD44FN
|
Bleomycin
|
Adult acute myeloid leukemia (Cell Line: HL-60(TB))
|
[3] |
|
Bleomycin + Pomalidomide
|
DCJO3JA
|
Bleomycin
|
Glioma (Cell Line: SF-295)
|
[3] |
|
Bleomycin + Pomalidomide
|
DCJXKAW
|
Bleomycin
|
Adenocarcinoma (Cell Line: HCC-2998)
|
[4] |
|
Bleomycin + Pomalidomide
|
DC1MCU3
|
Bleomycin
|
High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-4)
|
[4] |
|
Bleomycin + Pomalidomide
|
DCRJW5I
|
Bleomycin
|
High grade ovarian serous adenocarcinoma (Cell Line: NCI\\/ADR-RES)
|
[4] |
|
Bleomycin + Pomalidomide
|
DCSVCOA
|
Bleomycin
|
Lung adenocarcinoma (Cell Line: EKVX)
|
[4] |
|
Bleomycin + Pomalidomide
|
DCY4TH9
|
Bleomycin
|
Malignant melanoma (Cell Line: UACC62)
|
[4] |
|
Bortezomib + Pomalidomide
|
DCFCRRX
|
Bortezomib
|
Chronic myelogenous leukemia (Cell Line: KBM-7)
|
[3] |
|
Brincidofovir + Pomalidomide
|
DCLOGY3
|
Brincidofovir
|
Chronic myelogenous leukemia (Cell Line: KBM-7)
|
[3] |
|
Busulfan + Pomalidomide
|
DCO6NKP
|
Busulfan
|
Adenocarcinoma (Cell Line: OVCAR3)
|
[3] |
|
Busulfan + Pomalidomide
|
DCKEVOK
|
Busulfan
|
Adenocarcinoma (Cell Line: SW-620)
|
[3] |
|
Busulfan + Pomalidomide
|
DCXQD2K
|
Busulfan
|
Adult acute myeloid leukemia (Cell Line: HL-60(TB))
|
[3] |
|
Busulfan + Pomalidomide
|
DCRJS6O
|
Busulfan
|
Anaplastic large cell lymphoma (Cell Line: SR)
|
[3] |
|
Busulfan + Pomalidomide
|
DC5KH3F
|
Busulfan
|
Chronic myelogenous leukemia (Cell Line: K-562)
|
[3] |
|
Busulfan + Pomalidomide
|
DCAOGIH
|
Busulfan
|
High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-5)
|
[3] |
|
Busulfan + Pomalidomide
|
DC5I2KP
|
Busulfan
|
High grade ovarian serous adenocarcinoma (Cell Line: NCI\\/ADR-RES)
|
[3] |
|
Busulfan + Pomalidomide
|
DCZUTFP
|
Busulfan
|
Melanoma (Cell Line: MALME-3M)
|
[3] |
|
Busulfan + Pomalidomide
|
DCCI5KT
|
Busulfan
|
Carcinoma (Cell Line: RXF 393)
|
[5] |
|
Cabazitaxel + Pomalidomide
|
DCETYZZ
|
Cabazitaxel
|
Glioma (Cell Line: SF-295)
|
[3] |
|
Cabazitaxel + Pomalidomide
|
DCA6B1L
|
Cabazitaxel
|
Breast adenocarcinoma (Cell Line: MDA-MB-468)
|
[5] |
|
Cabazitaxel + Pomalidomide
|
DCH0E0R
|
Cabazitaxel
|
Colon adenocarcinoma (Cell Line: COLO 205)
|
[5] |
|
Crizotinib + Pomalidomide
|
DCX1HI0
|
Crizotinib
|
Adenocarcinoma (Cell Line: OVCAR3)
|
[3] |
|
Crizotinib + Pomalidomide
|
DCFIW61
|
Crizotinib
|
Amelanotic melanoma (Cell Line: M14)
|
[3] |
|
Crizotinib + Pomalidomide
|
DCDWVUY
|
Crizotinib
|
Astrocytoma (Cell Line: U251)
|
[3] |
|
Crizotinib + Pomalidomide
|
DC2EYVP
|
Crizotinib
|
Clear cell renal cell carcinoma (Cell Line: 786-0)
|
[3] |
|
Crizotinib + Pomalidomide
|
DC2JNDW
|
Crizotinib
|
Cutaneous melanoma (Cell Line: SK-MEL-5)
|
[3] |
|
Crizotinib + Pomalidomide
|
DC2PKYK
|
Crizotinib
|
Cutaneous melanoma (Cell Line: SK-MEL-28)
|
[3] |
|
Crizotinib + Pomalidomide
|
DCVNSKS
|
Crizotinib
|
Glioma (Cell Line: SF-539)
|
[3] |
|
Crizotinib + Pomalidomide
|
DC4XJKH
|
Crizotinib
|
High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-4)
|
[3] |
|
Crizotinib + Pomalidomide
|
DC278MO
|
Crizotinib
|
High grade ovarian serous adenocarcinoma (Cell Line: NCI\\/ADR-RES)
|
[3] |
|
Crizotinib + Pomalidomide
|
DC8GE8W
|
Crizotinib
|
Minimally invasive lung adenocarcinoma (Cell Line: NCI-H322M)
|
[3] |
|
Crizotinib + Pomalidomide
|
DCEXUHS
|
Crizotinib
|
Plasma cell myeloma (Cell Line: RPMI-8226)
|
[3] |
|
Crizotinib + Pomalidomide
|
DCRH4ZC
|
Crizotinib
|
Renal cell carcinoma (Cell Line: UO-31)
|
[3] |
|
Crizotinib + Pomalidomide
|
DCQN194
|
Crizotinib
|
Invasive ductal carcinoma (Cell Line: T-47D)
|
[5] |
|
Crizotinib + Pomalidomide
|
DC7M9RZ
|
Crizotinib
|
Invasive ductal carcinoma (Cell Line: BT-549)
|
[5] |
|
Dacarbazine + Pomalidomide
|
DCVFAEC
|
Dacarbazine
|
Adenocarcinoma (Cell Line: OVCAR3)
|
[3] |
|
Dacarbazine + Pomalidomide
|
DCQN1R8
|
Dacarbazine
|
Adenocarcinoma (Cell Line: HCC-2998)
|
[3] |
|
Dacarbazine + Pomalidomide
|
DCV3DR9
|
Dacarbazine
|
Adenocarcinoma (Cell Line: HCT116)
|
[3] |
|
Dacarbazine + Pomalidomide
|
DCYOO9G
|
Dacarbazine
|
Amelanotic melanoma (Cell Line: M14)
|
[3] |
|
Dacarbazine + Pomalidomide
|
DC82U5Z
|
Dacarbazine
|
Amelanotic melanoma (Cell Line: MDA-MB-435)
|
[3] |
|
Dacarbazine + Pomalidomide
|
DCZIREI
|
Dacarbazine
|
Childhood T acute lymphoblastic leukemia (Cell Line: CCRF-CEM)
|
[3] |
|
Dacarbazine + Pomalidomide
|
DCVGH9I
|
Dacarbazine
|
Clear cell renal cell carcinoma (Cell Line: 786-0)
|
[3] |
|
Dacarbazine + Pomalidomide
|
DC2JPD6
|
Dacarbazine
|
Clear cell renal cell carcinoma (Cell Line: CAKI-1)
|
[3] |
|
Dacarbazine + Pomalidomide
|
DCOLXFO
|
Dacarbazine
|
Glioblastoma (Cell Line: SNB-75)
|
[3] |
|
Dacarbazine + Pomalidomide
|
DCJEP9E
|
Dacarbazine
|
Glioma (Cell Line: SF-295)
|
[3] |
|
Dacarbazine + Pomalidomide
|
DC6O317
|
Dacarbazine
|
High grade ovarian serous adenocarcinoma (Cell Line: NCI\\/ADR-RES)
|
[3] |
|
Dacarbazine + Pomalidomide
|
DCL9STY
|
Dacarbazine
|
Lung adenocarcinoma (Cell Line: EKVX)
|
[3] |
|
Dacarbazine + Pomalidomide
|
DCLK467
|
Dacarbazine
|
Malignant melanoma (Cell Line: UACC62)
|
[3] |
|
Dacarbazine + Pomalidomide
|
DCLUQEH
|
Dacarbazine
|
Pleural epithelioid mesothelioma (Cell Line: NCI-H226)
|
[3] |
|
Dacarbazine + Pomalidomide
|
DC4DQYS
|
Dacarbazine
|
Renal cell carcinoma (Cell Line: SN12C)
|
[3] |
|
Dacarbazine + Pomalidomide
|
DCC250F
|
Dacarbazine
|
Colon carcinoma (Cell Line: KM12)
|
[5] |
|
Dacarbazine + Pomalidomide
|
DCY3692
|
Dacarbazine
|
Invasive ductal carcinoma (Cell Line: HS 578T)
|
[5] |
|
Dactinomycin + Pomalidomide
|
DCO04JA
|
Dactinomycin
|
Clear cell renal cell carcinoma (Cell Line: A498)
|
[4] |
|
Dasatinib + Pomalidomide
|
DCKF1EY
|
Dasatinib
|
Adenocarcinoma (Cell Line: DU-145)
|
[3] |
|
Dasatinib + Pomalidomide
|
DCRESTH
|
Dasatinib
|
Adenocarcinoma (Cell Line: SW-620)
|
[3] |
|
Dasatinib + Pomalidomide
|
DCJHKGS
|
Dasatinib
|
Adenocarcinoma (Cell Line: HCC-2998)
|
[3] |
|
Dasatinib + Pomalidomide
|
DC6JVYA
|
Dasatinib
|
Lung adenocarcinoma (Cell Line: NCI-H522)
|
[3] |
|
Dasatinib + Pomalidomide
|
DC8EHV9
|
Dasatinib
|
Melanoma (Cell Line: UACC-257)
|
[3] |
|
Dasatinib + Pomalidomide
|
DCM2MI9
|
Dasatinib
|
Minimally invasive lung adenocarcinoma (Cell Line: NCI-H322M)
|
[3] |
|
Dasatinib + Pomalidomide
|
DC02XXL
|
Dasatinib
|
Mixed endometrioid and clear cell carcinoma (Cell Line: IGROV1)
|
[3] |
|
Dasatinib + Pomalidomide
|
DCWB1H2
|
Dasatinib
|
Invasive ductal carcinoma (Cell Line: T-47D)
|
[5] |
|
Dexrazoxane + Pomalidomide
|
DC9LPXA
|
Dexrazoxane
|
Adult acute myeloid leukemia (Cell Line: HL-60(TB))
|
[3] |
|
Dexrazoxane + Pomalidomide
|
DCHIDTE
|
Dexrazoxane
|
Childhood T acute lymphoblastic leukemia (Cell Line: CCRF-CEM)
|
[3] |
|
Dexrazoxane + Pomalidomide
|
DCYHEMM
|
Dexrazoxane
|
Clear cell renal cell carcinoma (Cell Line: CAKI-1)
|
[3] |
|
Dexrazoxane + Pomalidomide
|
DCYMWKI
|
Dexrazoxane
|
Glioma (Cell Line: SF-295)
|
[3] |
|
Dexrazoxane + Pomalidomide
|
DC0ZC79
|
Dexrazoxane
|
Glioma (Cell Line: SF-268)
|
[3] |
|
Dexrazoxane + Pomalidomide
|
DCZSPZL
|
Dexrazoxane
|
Renal cell carcinoma (Cell Line: SN12C)
|
[3] |
|
Dexrazoxane + Pomalidomide
|
DCNSJ27
|
Dexrazoxane
|
Colon carcinoma (Cell Line: KM12)
|
[5] |
|
Dexrazoxane + Pomalidomide
|
DCPH0UH
|
Dexrazoxane
|
Adenocarcinoma (Cell Line: HT29)
|
[4] |
|
Dexrazoxane + Pomalidomide
|
DCI22I3
|
Dexrazoxane
|
Adenocarcinoma (Cell Line: HCT116)
|
[4] |
|
Dexrazoxane + Pomalidomide
|
DCXTCWJ
|
Dexrazoxane
|
Adenocarcinoma (Cell Line: SW-620)
|
[4] |
|
Dexrazoxane + Pomalidomide
|
DCIYIU1
|
Dexrazoxane
|
Lung adenocarcinoma (Cell Line: EKVX)
|
[4] |
|
Dexrazoxane + Pomalidomide
|
DCZQD0L
|
Dexrazoxane
|
Malignant melanoma (Cell Line: UACC62)
|
[4] |
|
DFN-15 + Pomalidomide
|
DCNVOIS
|
DFN-15
|
Astrocytoma (Cell Line: U251)
|
[3] |
|
DFN-15 + Pomalidomide
|
DC9PUFZ
|
DFN-15
|
High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-4)
|
[4] |
|
DFN-15 + Pomalidomide
|
DCL3VCY
|
DFN-15
|
Malignant melanoma (Cell Line: UACC62)
|
[4] |
|
Diazoxide + Pomalidomide
|
DCELEVM
|
Diazoxide
|
Chronic myelogenous leukemia (Cell Line: KBM-7)
|
[3] |
|
Diethylcarbamazine + Pomalidomide
|
DCPC8DX
|
Diethylcarbamazine
|
Chronic myelogenous leukemia (Cell Line: KBM-7)
|
[3] |
|
Digitoxin + Pomalidomide
|
DCUVUZD
|
Digitoxin
|
Glioblastoma (Cell Line: SNB-75)
|
[3] |
|
Diphenidol + Pomalidomide
|
DCQOAH0
|
Diphenidol
|
Chronic myelogenous leukemia (Cell Line: KBM-7)
|
[3] |
|
Docetaxel + Pomalidomide
|
DC4PD1Z
|
Docetaxel
|
Chronic myelogenous leukemia (Cell Line: K-562)
|
[3] |
|
Docetaxel + Pomalidomide
|
DC7E345
|
Docetaxel
|
Glioma (Cell Line: SF-295)
|
[3] |
|
Docetaxel + Pomalidomide
|
DCYJINE
|
Docetaxel
|
Breast adenocarcinoma (Cell Line: MDA-MB-468)
|
[5] |
|
Docetaxel + Pomalidomide
|
DCOECW6
|
Docetaxel
|
Colon adenocarcinoma (Cell Line: COLO 205)
|
[5] |
|
Docetaxel + Pomalidomide
|
DCUV2OZ
|
Docetaxel
|
Invasive ductal carcinoma (Cell Line: T-47D)
|
[5] |
|
Dronedarone + Pomalidomide
|
DCB5XIH
|
Dronedarone
|
Chronic myelogenous leukemia (Cell Line: KBM-7)
|
[3] |
|
Emetine + Pomalidomide
|
DCG98GD
|
Emetine
|
Chronic myelogenous leukemia (Cell Line: KBM-7)
|
[3] |
|
Endoxifen + Pomalidomide
|
DCH8JNI
|
Endoxifen
|
Chronic myelogenous leukemia (Cell Line: KBM-7)
|
[3] |
|
Epirubicin + Pomalidomide
|
DCAHPGN
|
Epirubicin
|
Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4)
|
[3] |
|
Epirubicin + Pomalidomide
|
DCYT3WH
|
Epirubicin
|
Astrocytoma (Cell Line: SNB-19)
|
[3] |
|
Epirubicin + Pomalidomide
|
DCNZ6XD
|
Epirubicin
|
Childhood T acute lymphoblastic leukemia (Cell Line: CCRF-CEM)
|
[3] |
|
Epirubicin + Pomalidomide
|
DC4TGFI
|
Epirubicin
|
Chronic myelogenous leukemia (Cell Line: K-562)
|
[3] |
|
Epirubicin + Pomalidomide
|
DCWUG1R
|
Epirubicin
|
Clear cell renal cell carcinoma (Cell Line: TK-10)
|
[3] |
|
Epirubicin + Pomalidomide
|
DCHTSZD
|
Epirubicin
|
Clear cell renal cell carcinoma (Cell Line: A498)
|
[3] |
|
Epirubicin + Pomalidomide
|
DCPEMOD
|
Epirubicin
|
Clear cell renal cell carcinoma (Cell Line: 786-0)
|
[3] |
|
Epirubicin + Pomalidomide
|
DC29C7Q
|
Epirubicin
|
Glioma (Cell Line: SF-268)
|
[3] |
|
Epirubicin + Pomalidomide
|
DCIFIFH
|
Epirubicin
|
Carcinoma (Cell Line: RXF 393)
|
[5] |
|
Epirubicin + Pomalidomide
|
DC30ATM
|
Epirubicin
|
Carcinoma (Cell Line: MCF7)
|
[5] |
|
Epirubicin + Pomalidomide
|
DC47Z24
|
Epirubicin
|
Colon carcinoma (Cell Line: KM12)
|
[5] |
|
Epirubicin + Pomalidomide
|
DCEXUTT
|
Epirubicin
|
Invasive ductal carcinoma (Cell Line: HS 578T)
|
[5] |
|
Epirubicin + Pomalidomide
|
DCOR888
|
Epirubicin
|
Invasive ductal carcinoma (Cell Line: BT-549)
|
[5] |
|
Epirubicin + Pomalidomide
|
DC9C35Q
|
Epirubicin
|
Adenocarcinoma (Cell Line: DU-145)
|
[4] |
|
Epirubicin + Pomalidomide
|
DCKYPJT
|
Epirubicin
|
Adenocarcinoma (Cell Line: OVCAR3)
|
[4] |
|
Epirubicin + Pomalidomide
|
DC957Q6
|
Epirubicin
|
Adenocarcinoma (Cell Line: HCT116)
|
[4] |
|
Epirubicin + Pomalidomide
|
DCUL0OE
|
Epirubicin
|
Amelanotic melanoma (Cell Line: MDA-MB-435)
|
[4] |
|
Epirubicin + Pomalidomide
|
DCBAKL9
|
Epirubicin
|
Amelanotic melanoma (Cell Line: M14)
|
[4] |
|
Epirubicin + Pomalidomide
|
DCITQRR
|
Epirubicin
|
Cutaneous melanoma (Cell Line: SK-MEL-28)
|
[4] |
|
Epirubicin + Pomalidomide
|
DCLSYCA
|
Epirubicin
|
High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-5)
|
[4] |
|
Epirubicin + Pomalidomide
|
DCU7R6F
|
Epirubicin
|
High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-8)
|
[4] |
|
Epirubicin + Pomalidomide
|
DCXDJWC
|
Epirubicin
|
High grade ovarian serous adenocarcinoma (Cell Line: NCI\\/ADR-RES)
|
[4] |
|
Epirubicin + Pomalidomide
|
DCRPZ07
|
Epirubicin
|
Lung adenocarcinoma (Cell Line: EKVX)
|
[4] |
|
Epirubicin + Pomalidomide
|
DCDRERE
|
Epirubicin
|
Lung adenocarcinoma (Cell Line: NCI-H522)
|
[4] |
|
Epirubicin + Pomalidomide
|
DC42R3P
|
Epirubicin
|
Malignant melanoma (Cell Line: UACC62)
|
[4] |
|
Epirubicin + Pomalidomide
|
DCRMTEP
|
Epirubicin
|
Melanoma (Cell Line: SK-MEL-2)
|
[4] |
|
Epirubicin + Pomalidomide
|
DCIF9VP
|
Epirubicin
|
Melanoma (Cell Line: UACC-257)
|
[4] |
|
Epirubicin + Pomalidomide
|
DCPUDO8
|
Epirubicin
|
Melanoma (Cell Line: MALME-3M)
|
[4] |
|
Epirubicin + Pomalidomide
|
DCL8Z2Y
|
Epirubicin
|
Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3)
|
[4] |
|
Epirubicin + Pomalidomide
|
DCQ5X84
|
Epirubicin
|
Pleural epithelioid mesothelioma (Cell Line: NCI-H226)
|
[4] |
|
Estramustine + Pomalidomide
|
DCG00ZI
|
Estramustine
|
Clear cell renal cell carcinoma (Cell Line: TK-10)
|
[3] |
|
Estramustine + Pomalidomide
|
DCSQM1O
|
Estramustine
|
Invasive ductal carcinoma (Cell Line: HS 578T)
|
[5] |
|
Estramustine + Pomalidomide
|
DCJQ3DP
|
Estramustine
|
Adenocarcinoma (Cell Line: OVCAR3)
|
[4] |
|
Estramustine + Pomalidomide
|
DCNEM58
|
Estramustine
|
Lung adenocarcinoma (Cell Line: HOP-62)
|
[4] |
|
Estramustine + Pomalidomide
|
DC9C68W
|
Estramustine
|
Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3)
|
[4] |
|
Everolimus + Pomalidomide
|
DCXE6A9
|
Everolimus
|
Chronic myelogenous leukemia (Cell Line: KBM-7)
|
[3] |
|
Ezetimibe + Pomalidomide
|
DC550HZ
|
Ezetimibe
|
Chronic myelogenous leukemia (Cell Line: KBM-7)
|
[3] |
|
Fludarabine + Pomalidomide
|
DCB20LR
|
Fludarabine
|
Invasive ductal carcinoma (Cell Line: HS 578T)
|
[5] |
|
Fomepizole + Pomalidomide
|
DCR9DOF
|
Fomepizole
|
Chronic myelogenous leukemia (Cell Line: KBM-7)
|
[3] |
|
FORMESTANE + Pomalidomide
|
DCLKJYT
|
FORMESTANE
|
Adenocarcinoma (Cell Line: HT29)
|
[3] |
|
FORMESTANE + Pomalidomide
|
DCPT35K
|
FORMESTANE
|
Chronic myelogenous leukemia (Cell Line: KBM-7)
|
[3] |
|
FORMESTANE + Pomalidomide
|
DCVH1KL
|
FORMESTANE
|
Glioma (Cell Line: SF-539)
|
[3] |
|
FORMESTANE + Pomalidomide
|
DC7367P
|
FORMESTANE
|
Malignant melanoma (Cell Line: UACC62)
|
[3] |
|
Fosfomycin + Pomalidomide
|
DCTQ8AF
|
Fosfomycin
|
Chronic myelogenous leukemia (Cell Line: KBM-7)
|
[3] |
|
Fulvestrant + Pomalidomide
|
DCXSGPQ
|
Fulvestrant
|
Astrocytoma (Cell Line: SNB-19)
|
[3] |
|
Fulvestrant + Pomalidomide
|
DCBTO8I
|
Fulvestrant
|
Clear cell renal cell carcinoma (Cell Line: TK-10)
|
[3] |
|
Fulvestrant + Pomalidomide
|
DCNXEO9
|
Fulvestrant
|
Lung adenocarcinoma (Cell Line: HOP-62)
|
[3] |
|
Fulvestrant + Pomalidomide
|
DCYSK0D
|
Fulvestrant
|
Melanoma (Cell Line: MALME-3M)
|
[3] |
|
Gefitinib + Pomalidomide
|
DCQ383X
|
Gefitinib
|
Glioma (Cell Line: SF-268)
|
[3] |
|
Gefitinib + Pomalidomide
|
DCBTDDE
|
Gefitinib
|
Lung adenocarcinoma (Cell Line: HOP-62)
|
[3] |
|
Gefitinib + Pomalidomide
|
DC6W5CB
|
Gefitinib
|
Renal cell carcinoma (Cell Line: SN12C)
|
[3] |
|
GSK2194069 + Pomalidomide
|
DCCUV9B
|
GSK2194069
|
Chronic myelogenous leukemia (Cell Line: KBM-7)
|
[3] |
|
Hepzato + Pomalidomide
|
DCK5MTN
|
Hepzato
|
Breast adenocarcinoma (Cell Line: MDA-MB-468)
|
[5] |
|
Hepzato + Pomalidomide
|
DCCHTKD
|
Hepzato
|
Lung adenocarcinoma (Cell Line: EKVX)
|
[4] |
|
Hepzato + Pomalidomide
|
DC29O22
|
Hepzato
|
Lung adenocarcinoma (Cell Line: MDA-MB-231)
|
[4] |
|
Hepzato + Pomalidomide
|
DCOEIP9
|
Hepzato
|
Non-small cell lung carcinoma (Cell Line: HOP-92)
|
[4] |
|
Hyodeoxycholic acid + Pomalidomide
|
DCSSFSS
|
Hyodeoxycholic acid
|
Chronic myelogenous leukemia (Cell Line: KBM-7)
|
[3] |
|
Idarubicin + Pomalidomide
|
DC3SRBJ
|
Idarubicin
|
Astrocytoma (Cell Line: U251)
|
[3] |
|
Idarubicin + Pomalidomide
|
DCZNZ2U
|
Idarubicin
|
Clear cell renal cell carcinoma (Cell Line: 786-0)
|
[3] |
|
Idarubicin + Pomalidomide
|
DC6O30T
|
Idarubicin
|
Renal cell carcinoma (Cell Line: SN12C)
|
[3] |
|
Idarubicin + Pomalidomide
|
DCOGQ7O
|
Idarubicin
|
Adenocarcinoma (Cell Line: HCC-2998)
|
[4] |
|
Idarubicin + Pomalidomide
|
DCII0GJ
|
Idarubicin
|
Adenocarcinoma (Cell Line: HCT116)
|
[4] |
|
Idarubicin + Pomalidomide
|
DC6KVPO
|
Idarubicin
|
High grade ovarian serous adenocarcinoma (Cell Line: NCI\\/ADR-RES)
|
[4] |
|
Idarubicin + Pomalidomide
|
DC821O5
|
Idarubicin
|
Mixed endometrioid and clear cell carcinoma (Cell Line: IGROV1)
|
[4] |
|
Imatinib + Pomalidomide
|
DCUE5BD
|
Imatinib
|
Malignant melanoma (Cell Line: LOX IMVI)
|
[3] |
|
Indazole derivative 5 + Pomalidomide
|
DCD4VBU
|
Indazole derivative 5
|
Clear cell renal cell carcinoma (Cell Line: 786-0)
|
[3] |
|
Indazole derivative 5 + Pomalidomide
|
DCVS791
|
Indazole derivative 5
|
Clear cell renal cell carcinoma (Cell Line: A498)
|
[3] |
|
Indazole derivative 5 + Pomalidomide
|
DCMAOGC
|
Indazole derivative 5
|
Renal cell carcinoma (Cell Line: UO-31)
|
[3] |
|
Indazole derivative 5 + Pomalidomide
|
DC5MGZS
|
Indazole derivative 5
|
Colon adenocarcinoma (Cell Line: COLO 205)
|
[5] |
|
Indazole derivative 5 + Pomalidomide
|
DCB7BS8
|
Indazole derivative 5
|
Invasive ductal carcinoma (Cell Line: T-47D)
|
[5] |
|
Indazole derivative 5 + Pomalidomide
|
DCA8X0H
|
Indazole derivative 5
|
Invasive ductal carcinoma (Cell Line: BT-549)
|
[5] |
|
Indazole derivative 5 + Pomalidomide
|
DCC6U60
|
Indazole derivative 5
|
Adenocarcinoma (Cell Line: OVCAR3)
|
[4] |
|
Indazole derivative 5 + Pomalidomide
|
DC6SVTS
|
Indazole derivative 5
|
Adenocarcinoma (Cell Line: NCIH23)
|
[4] |
|
Indazole derivative 5 + Pomalidomide
|
DCWYOS2
|
Indazole derivative 5
|
Adenocarcinoma (Cell Line: HT29)
|
[4] |
|
Indazole derivative 5 + Pomalidomide
|
DCJAPON
|
Indazole derivative 5
|
Cutaneous melanoma (Cell Line: SK-MEL-5)
|
[4] |
|
Indazole derivative 5 + Pomalidomide
|
DCKPCNO
|
Indazole derivative 5
|
High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-8)
|
[4] |
|
Indazole derivative 5 + Pomalidomide
|
DC8USQL
|
Indazole derivative 5
|
High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-5)
|
[4] |
|
Indazole derivative 5 + Pomalidomide
|
DC9P78U
|
Indazole derivative 5
|
High grade ovarian serous adenocarcinoma (Cell Line: NCI\\/ADR-RES)
|
[4] |
|
Indazole derivative 5 + Pomalidomide
|
DC3IS2M
|
Indazole derivative 5
|
Melanoma (Cell Line: UACC-257)
|
[4] |
|
Indazole derivative 5 + Pomalidomide
|
DC8S74I
|
Indazole derivative 5
|
Non-small cell lung carcinoma (Cell Line: HOP-92)
|
[4] |
|
Indazole derivative 5 + Pomalidomide
|
DCNP5SI
|
Indazole derivative 5
|
Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3)
|
[4] |
|
Indazole derivative 5 + Pomalidomide
|
DCTYX8C
|
Indazole derivative 5
|
Pleural epithelioid mesothelioma (Cell Line: NCI-H226)
|
[4] |
|
JNK-IN-8 + Pomalidomide
|
DCIDAAE
|
JNK-IN-8
|
Glioma (Cell Line: SF-295)
|
[3] |
|
JNK-IN-8 + Pomalidomide
|
DC6CA0M
|
JNK-IN-8
|
Renal cell carcinoma (Cell Line: SN12C)
|
[3] |
|
JNK-IN-8 + Pomalidomide
|
DCNCMFT
|
JNK-IN-8
|
Malignant melanoma (Cell Line: UACC62)
|
[4] |
|
Lapatinib + Pomalidomide
|
DCKY3A1
|
Lapatinib
|
Carcinoma (Cell Line: RXF 393)
|
[5] |
|
Lapatinib + Pomalidomide
|
DCVOF1G
|
Lapatinib
|
Invasive ductal carcinoma (Cell Line: HS 578T)
|
[5] |
|
Lapatinib + Pomalidomide
|
DCUFEC4
|
Lapatinib
|
Adenocarcinoma (Cell Line: NCIH23)
|
[4] |
|
Lapatinib + Pomalidomide
|
DC5RSJB
|
Lapatinib
|
Adenocarcinoma (Cell Line: A549)
|
[4] |
|
Lapatinib + Pomalidomide
|
DCK3WXV
|
Lapatinib
|
Adenocarcinoma (Cell Line: HCT116)
|
[4] |
|
Lapatinib + Pomalidomide
|
DCHS4T8
|
Lapatinib
|
Adult acute myeloid leukemia (Cell Line: HL-60(TB))
|
[4] |
|
Lapatinib + Pomalidomide
|
DCO62JX
|
Lapatinib
|
Malignant melanoma (Cell Line: UACC62)
|
[4] |
|
Leflunomide + Pomalidomide
|
DCJZNT8
|
Leflunomide
|
Chronic myelogenous leukemia (Cell Line: KBM-7)
|
[3] |
|
Lenalidomide + Pomalidomide
|
DCV867J
|
Lenalidomide
|
Renal cell carcinoma (Cell Line: SN12C)
|
[3] |
|
Lenalidomide + Pomalidomide
|
DC8525P
|
Lenalidomide
|
Colon carcinoma (Cell Line: KM12)
|
[5] |
|
Lenalidomide + Pomalidomide
|
DCOV7X0
|
Lenalidomide
|
Invasive ductal carcinoma (Cell Line: BT-549)
|
[5] |
|
Lenalidomide + Pomalidomide
|
DC32NWC
|
Lenalidomide
|
Adenocarcinoma (Cell Line: HCC-2998)
|
[4] |
|
Lenalidomide + Pomalidomide
|
DC1EIU2
|
Lenalidomide
|
Cutaneous melanoma (Cell Line: SK-MEL-28)
|
[4] |
|
Lenalidomide + Pomalidomide
|
DCZ6DN7
|
Lenalidomide
|
High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-4)
|
[4] |
|
Lenalidomide + Pomalidomide
|
DCKCUDH
|
Lenalidomide
|
Pleural epithelioid mesothelioma (Cell Line: NCI-H226)
|
[4] |
|
Letrozole + Pomalidomide
|
DCUG40I
|
Letrozole
|
Astrocytoma (Cell Line: U251)
|
[3] |
|
Letrozole + Pomalidomide
|
DC5IY5U
|
Letrozole
|
Childhood T acute lymphoblastic leukemia (Cell Line: CCRF-CEM)
|
[3] |
|
Letrozole + Pomalidomide
|
DC677ZX
|
Letrozole
|
Chronic myelogenous leukemia (Cell Line: K-562)
|
[3] |
|
Letrozole + Pomalidomide
|
DC410IM
|
Letrozole
|
High grade ovarian serous adenocarcinoma (Cell Line: NCI\\/ADR-RES)
|
[3] |
|
Letrozole + Pomalidomide
|
DCVHIP6
|
Letrozole
|
Lung adenocarcinoma (Cell Line: HOP-62)
|
[3] |
|
Letrozole + Pomalidomide
|
DC0L05U
|
Letrozole
|
Non-small cell lung carcinoma (Cell Line: HOP-92)
|
[3] |
|
Letrozole + Pomalidomide
|
DCR7SQD
|
Letrozole
|
Carcinoma (Cell Line: RXF 393)
|
[5] |
|
Letrozole + Pomalidomide
|
DC4RTES
|
Letrozole
|
Invasive ductal carcinoma (Cell Line: T-47D)
|
[5] |
|
LIAROZOLE + Pomalidomide
|
DCQZ3BP
|
LIAROZOLE
|
Adenocarcinoma (Cell Line: OVCAR3)
|
[4] |
|
Lithium Citrate + Pomalidomide
|
DCPF4XG
|
Lithium Citrate
|
Chronic myelogenous leukemia (Cell Line: KBM-7)
|
[3] |
|
Mechlorethamine + Pomalidomide
|
DCFHBBU
|
Mechlorethamine
|
Adult acute myeloid leukemia (Cell Line: HL-60(TB))
|
[3] |
|
Mechlorethamine + Pomalidomide
|
DCMEMC7
|
Mechlorethamine
|
Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4)
|
[3] |
|
Mechlorethamine + Pomalidomide
|
DCHRAF0
|
Mechlorethamine
|
Childhood T acute lymphoblastic leukemia (Cell Line: CCRF-CEM)
|
[3] |
|
Mechlorethamine + Pomalidomide
|
DCOUD09
|
Mechlorethamine
|
Clear cell renal cell carcinoma (Cell Line: 786-0)
|
[3] |
|
Mechlorethamine + Pomalidomide
|
DCWFYJN
|
Mechlorethamine
|
Clear cell renal cell carcinoma (Cell Line: CAKI-1)
|
[3] |
|
Mechlorethamine + Pomalidomide
|
DCTLYTO
|
Mechlorethamine
|
Glioblastoma (Cell Line: SNB-75)
|
[3] |
|
Mechlorethamine + Pomalidomide
|
DCMELCS
|
Mechlorethamine
|
Glioma (Cell Line: SF-295)
|
[3] |
|
Mechlorethamine + Pomalidomide
|
DC1NRWG
|
Mechlorethamine
|
Plasma cell myeloma (Cell Line: RPMI-8226)
|
[3] |
|
Mechlorethamine + Pomalidomide
|
DCR8PC8
|
Mechlorethamine
|
Renal cell carcinoma (Cell Line: SN12C)
|
[3] |
|
Mechlorethamine + Pomalidomide
|
DCTAJ57
|
Mechlorethamine
|
Carcinoma (Cell Line: RXF 393)
|
[5] |
|
Mechlorethamine + Pomalidomide
|
DCCASKI
|
Mechlorethamine
|
Colon carcinoma (Cell Line: KM12)
|
[5] |
|
Mechlorethamine + Pomalidomide
|
DCTEOC1
|
Mechlorethamine
|
Adenocarcinoma (Cell Line: HCT116)
|
[4] |
|
Mechlorethamine + Pomalidomide
|
DC94RWB
|
Mechlorethamine
|
Adenocarcinoma (Cell Line: HCC-2998)
|
[4] |
|
Mechlorethamine + Pomalidomide
|
DCR9RM2
|
Mechlorethamine
|
Amelanotic melanoma (Cell Line: M14)
|
[4] |
|
Mechlorethamine + Pomalidomide
|
DCZD9PK
|
Mechlorethamine
|
High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-4)
|
[4] |
|
Mechlorethamine + Pomalidomide
|
DC39MQT
|
Mechlorethamine
|
High grade ovarian serous adenocarcinoma (Cell Line: NCI\\/ADR-RES)
|
[4] |
|
Mechlorethamine + Pomalidomide
|
DCKI64Q
|
Mechlorethamine
|
Lung adenocarcinoma (Cell Line: EKVX)
|
[4] |
|
Mechlorethamine + Pomalidomide
|
DCASP9E
|
Mechlorethamine
|
Malignant melanoma (Cell Line: UACC62)
|
[4] |
|
Mechlorethamine + Pomalidomide
|
DCKSJA8
|
Mechlorethamine
|
Non-small cell lung carcinoma (Cell Line: HOP-92)
|
[4] |
|
Mepacrine + Pomalidomide
|
DCIJNOZ
|
Mepacrine
|
Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4)
|
[3] |
|
Mepacrine + Pomalidomide
|
DC8OWIZ
|
Mepacrine
|
Adenocarcinoma (Cell Line: OVCAR3)
|
[4] |
|
Mepacrine + Pomalidomide
|
DCBKVF8
|
Mepacrine
|
Melanoma (Cell Line: UACC-257)
|
[4] |
|
Methocarbamol + Pomalidomide
|
DCQAUZT
|
Methocarbamol
|
Chronic myelogenous leukemia (Cell Line: KBM-7)
|
[3] |
|
Methotrexate + Pomalidomide
|
DC1B9WO
|
Methotrexate
|
Chronic myelogenous leukemia (Cell Line: KBM-7)
|
[3] |
|
Methotrexate + Pomalidomide
|
DC6TA2Z
|
Methotrexate
|
Melanoma (Cell Line: MALME-3M)
|
[3] |
|
Nilotinib + Pomalidomide
|
DCU18UH
|
Nilotinib
|
Adenocarcinoma (Cell Line: HCC-2998)
|
[4] |
|
Nilotinib + Pomalidomide
|
DCR8S0K
|
Nilotinib
|
Non-small cell lung carcinoma (Cell Line: HOP-92)
|
[4] |
|
Norcisapride + Pomalidomide
|
DCCY9G1
|
Norcisapride
|
Chronic myelogenous leukemia (Cell Line: KBM-7)
|
[3] |
|
Picoplatin + Pomalidomide
|
DCIJ7RC
|
Picoplatin
|
Astrocytoma (Cell Line: U251)
|
[3] |
|
Picoplatin + Pomalidomide
|
DC1ZPM9
|
Picoplatin
|
Childhood T acute lymphoblastic leukemia (Cell Line: CCRF-CEM)
|
[3] |
|
Picoplatin + Pomalidomide
|
DCKSW38
|
Picoplatin
|
Clear cell renal cell carcinoma (Cell Line: 786-0)
|
[3] |
|
Picoplatin + Pomalidomide
|
DC0KFPH
|
Picoplatin
|
Clear cell renal cell carcinoma (Cell Line: CAKI-1)
|
[3] |
|
Picoplatin + Pomalidomide
|
DCDGOP1
|
Picoplatin
|
Glioblastoma (Cell Line: SNB-75)
|
[3] |
|
Picoplatin + Pomalidomide
|
DC2FD0V
|
Picoplatin
|
Glioma (Cell Line: SF-539)
|
[3] |
|
Picoplatin + Pomalidomide
|
DCZ71RP
|
Picoplatin
|
Glioma (Cell Line: SF-295)
|
[3] |
|
Picoplatin + Pomalidomide
|
DCNPNEF
|
Picoplatin
|
Renal cell carcinoma (Cell Line: SN12C)
|
[3] |
|
Picoplatin + Pomalidomide
|
DC9OD1Y
|
Picoplatin
|
Colon carcinoma (Cell Line: KM12)
|
[5] |
|
Picoplatin + Pomalidomide
|
DC4RO2Q
|
Picoplatin
|
Adenocarcinoma (Cell Line: OVCAR3)
|
[4] |
|
Picoplatin + Pomalidomide
|
DCKIOHH
|
Picoplatin
|
Adenocarcinoma (Cell Line: NCIH23)
|
[4] |
|
Picoplatin + Pomalidomide
|
DCX9MAV
|
Picoplatin
|
Adenocarcinoma (Cell Line: HCT116)
|
[4] |
|
Picoplatin + Pomalidomide
|
DCKKTIO
|
Picoplatin
|
Adenocarcinoma (Cell Line: HT29)
|
[4] |
|
Picoplatin + Pomalidomide
|
DC9HBXB
|
Picoplatin
|
Amelanotic melanoma (Cell Line: M14)
|
[4] |
|
Picoplatin + Pomalidomide
|
DCX110E
|
Picoplatin
|
Amelanotic melanoma (Cell Line: MDA-MB-435)
|
[4] |
|
Picoplatin + Pomalidomide
|
DCMC1M7
|
Picoplatin
|
High grade ovarian serous adenocarcinoma (Cell Line: NCI\\/ADR-RES)
|
[4] |
|
Picoplatin + Pomalidomide
|
DCZHC1T
|
Picoplatin
|
Lung adenocarcinoma (Cell Line: EKVX)
|
[4] |
|
Picoplatin + Pomalidomide
|
DCBTK9L
|
Picoplatin
|
Lung adenocarcinoma (Cell Line: NCI-H522)
|
[4] |
|
Picoplatin + Pomalidomide
|
DCD72RJ
|
Picoplatin
|
Malignant melanoma (Cell Line: UACC62)
|
[4] |
|
Picoplatin + Pomalidomide
|
DCK1I2O
|
Picoplatin
|
Minimally invasive lung adenocarcinoma (Cell Line: NCI-H322M)
|
[4] |
|
Picoplatin + Pomalidomide
|
DCZ2YL3
|
Picoplatin
|
Mixed endometrioid and clear cell carcinoma (Cell Line: IGROV1)
|
[4] |
|
Picoplatin + Pomalidomide
|
DCENK0E
|
Picoplatin
|
Non-small cell lung carcinoma (Cell Line: HOP-92)
|
[4] |
|
Picoplatin + Pomalidomide
|
DCDY8F1
|
Picoplatin
|
Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3)
|
[4] |
|
Picoplatin + Pomalidomide
|
DC40SUG
|
Picoplatin
|
Pleural epithelioid mesothelioma (Cell Line: NCI-H226)
|
[4] |
|
Plicamycin + Pomalidomide
|
DCNA6L8
|
Plicamycin
|
Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4)
|
[3] |
|
Plicamycin + Pomalidomide
|
DCT1OX5
|
Plicamycin
|
Astrocytoma (Cell Line: U251)
|
[3] |
|
Plicamycin + Pomalidomide
|
DC5LIHY
|
Plicamycin
|
Astrocytoma (Cell Line: SNB-19)
|
[3] |
|
Plicamycin + Pomalidomide
|
DCMEW3W
|
Plicamycin
|
Clear cell renal cell carcinoma (Cell Line: 786-0)
|
[3] |
|
Plicamycin + Pomalidomide
|
DCDUY2I
|
Plicamycin
|
Clear cell renal cell carcinoma (Cell Line: A498)
|
[3] |
|
Plicamycin + Pomalidomide
|
DCDPZ6C
|
Plicamycin
|
Renal cell carcinoma (Cell Line: SN12C)
|
[3] |
|
Plicamycin + Pomalidomide
|
DCJ4BTN
|
Plicamycin
|
Breast adenocarcinoma (Cell Line: MDA-MB-468)
|
[5] |
|
Plicamycin + Pomalidomide
|
DC3VV45
|
Plicamycin
|
Adenocarcinoma (Cell Line: NCIH23)
|
[4] |
|
PMID28460551-Compound-2 + Pomalidomide
|
DCHUJDB
|
PMID28460551-Compound-2
|
Adenocarcinoma (Cell Line: HCC-2998)
|
[4] |
|
PMID28870136-Compound-43 + Pomalidomide
|
DC22U3P
|
PMID28870136-Compound-43
|
Invasive ductal carcinoma (Cell Line: BT-549)
|
[5] |
|
PMID28870136-Compound-43 + Pomalidomide
|
DCV97GF
|
PMID28870136-Compound-43
|
Invasive ductal carcinoma (Cell Line: HS 578T)
|
[5] |
|
PMID28870136-Compound-43 + Pomalidomide
|
DCH944G
|
PMID28870136-Compound-43
|
Adenocarcinoma (Cell Line: HCT116)
|
[4] |
|
PMID28870136-Compound-43 + Pomalidomide
|
DCHP06K
|
PMID28870136-Compound-43
|
Amelanotic melanoma (Cell Line: M14)
|
[4] |
|
PMID28870136-Compound-43 + Pomalidomide
|
DCGM4C4
|
PMID28870136-Compound-43
|
High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-8)
|
[4] |
|
PMID28870136-Compound-43 + Pomalidomide
|
DCQ8F81
|
PMID28870136-Compound-43
|
High grade ovarian serous adenocarcinoma (Cell Line: NCI\\/ADR-RES)
|
[4] |
|
Pomalidomide + Aprepitant
|
DCB0SI1
|
Aprepitant
|
Chronic myelogenous leukemia (Cell Line: KBM-7)
|
[3] |
|
Pomalidomide + Ribavirin-TP
|
DCV8WWJ
|
Ribavirin-TP
|
Chronic myelogenous leukemia (Cell Line: KBM-7)
|
[3] |
|
Pomalidomide + Pentostatin
|
DC3C3UW
|
Pentostatin
|
Adenocarcinoma (Cell Line: HCC-2998)
|
[3] |
|
Pomalidomide + Pentostatin
|
DC8DWJQ
|
Pentostatin
|
Amelanotic melanoma (Cell Line: MDA-MB-435)
|
[3] |
|
Pomalidomide + Pentostatin
|
DCR3KEJ
|
Pentostatin
|
Anaplastic large cell lymphoma (Cell Line: SR)
|
[3] |
|
Pomalidomide + Pentostatin
|
DC6LVQJ
|
Pentostatin
|
Lung adenocarcinoma (Cell Line: NCI-H522)
|
[3] |
|
Pomalidomide + Bepridil
|
DCSSOK3
|
Bepridil
|
Chronic myelogenous leukemia (Cell Line: KBM-7)
|
[3] |
|
Pomalidomide + Gefitinib
|
DCZZ1KR
|
Gefitinib
|
Chronic myelogenous leukemia (Cell Line: KBM-7)
|
[3] |
|
Pomalidomide + Dantrolene
|
DCUVCI8
|
Dantrolene
|
Chronic myelogenous leukemia (Cell Line: KBM-7)
|
[3] |
|
Pomalidomide + Diethylcarbamazine
|
DCJ1E0Z
|
Diethylcarbamazine
|
Chronic myelogenous leukemia (Cell Line: KBM-7)
|
[3] |
|
Pomalidomide + Lumefantrine
|
DCVL0MT
|
Lumefantrine
|
Chronic myelogenous leukemia (Cell Line: KBM-7)
|
[3] |
|
Pomalidomide + Ixabepilone
|
DC90BIP
|
Ixabepilone
|
Adenocarcinoma (Cell Line: HT29)
|
[3] |
|
Pomalidomide + Epinephrine
|
DC0918Q
|
Epinephrine
|
Chronic myelogenous leukemia (Cell Line: KBM-7)
|
[3] |
|
Pomalidomide + Chlorphenesin
|
DCEXI5S
|
Chlorphenesin
|
Chronic myelogenous leukemia (Cell Line: KBM-7)
|
[3] |
|
Pomalidomide + PMID28460551-Compound-2
|
DC3004Y
|
PMID28460551-Compound-2
|
Chronic myelogenous leukemia (Cell Line: KBM-7)
|
[3] |
|
Pomalidomide + Cyclophosphamide
|
DC1DK1F
|
Cyclophosphamide
|
Adult acute myeloid leukemia (Cell Line: HL-60(TB))
|
[3] |
|
Pomalidomide + Cyclophosphamide
|
DCL2IA5
|
Cyclophosphamide
|
Glioma (Cell Line: SF-539)
|
[3] |
|
Pomalidomide + Cyclophosphamide
|
DC0X7EJ
|
Cyclophosphamide
|
Malignant melanoma (Cell Line: UACC62)
|
[3] |
|
Pomalidomide + Isoniazid
|
DCM2P3G
|
Isoniazid
|
Adenocarcinoma (Cell Line: A549)
|
[3] |
|
Pomalidomide + Isoniazid
|
DCZ38KL
|
Isoniazid
|
Chronic myelogenous leukemia (Cell Line: K-562)
|
[3] |
|
Pomalidomide + Isoniazid
|
DC3PFES
|
Isoniazid
|
Clear cell renal cell carcinoma (Cell Line: 786-0)
|
[3] |
|
Pomalidomide + Isoniazid
|
DCB20OR
|
Isoniazid
|
Lung adenocarcinoma (Cell Line: NCI-H522)
|
[3] |
|
Pomalidomide + Anamorelin
|
DC8IL6D
|
Anamorelin
|
Chronic myelogenous leukemia (Cell Line: KBM-7)
|
[3] |
|
Pomalidomide + Ifosfamide
|
DCZPIRI
|
Ifosfamide
|
Adenocarcinoma (Cell Line: A549)
|
[3] |
|
Pomalidomide + Ifosfamide
|
DC9ITFC
|
Ifosfamide
|
Adenocarcinoma (Cell Line: HT29)
|
[3] |
|
Pomalidomide + Ifosfamide
|
DCW7NDN
|
Ifosfamide
|
Adenocarcinoma (Cell Line: HCT116)
|
[3] |
|
Pomalidomide + Ifosfamide
|
DCGCG7G
|
Ifosfamide
|
Cutaneous melanoma (Cell Line: SK-MEL-28)
|
[3] |
|
Pomalidomide + Ifosfamide
|
DC5KGQ7
|
Ifosfamide
|
Lung adenocarcinoma (Cell Line: HOP-62)
|
[3] |
|
Pomalidomide + Ifosfamide
|
DC8Q9HP
|
Ifosfamide
|
Malignant melanoma (Cell Line: LOX IMVI)
|
[3] |
|
Pomalidomide + Docetaxel
|
DCODMVR
|
Docetaxel
|
Chronic myelogenous leukemia (Cell Line: KBM-7)
|
[3] |
|
Pomalidomide + JZL195
|
DC4A5LL
|
JZL195
|
Chronic myelogenous leukemia (Cell Line: KBM-7)
|
[3] |
|
Pomalidomide + Mitomycin
|
DCJXJCL
|
Mitomycin
|
Adenocarcinoma (Cell Line: DU-145)
|
[3] |
|
Pomalidomide + Mitomycin
|
DC3T8P5
|
Mitomycin
|
Adenocarcinoma (Cell Line: A549)
|
[3] |
|
Pomalidomide + Mitomycin
|
DCPEVNP
|
Mitomycin
|
Astrocytoma (Cell Line: SNB-19)
|
[3] |
|
Pomalidomide + Mitomycin
|
DCPX2W6
|
Mitomycin
|
Cutaneous melanoma (Cell Line: SK-MEL-28)
|
[3] |
|
Pomalidomide + Mitomycin
|
DCXZLRW
|
Mitomycin
|
High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-5)
|
[3] |
|
Pomalidomide + Mitomycin
|
DCU9THN
|
Mitomycin
|
Large cell lung carcinoma (Cell Line: NCI-H460)
|
[3] |
|
Pomalidomide + Mitomycin
|
DCYQIDI
|
Mitomycin
|
Lung adenocarcinoma (Cell Line: HOP-62)
|
[3] |
|
Pomalidomide + Mitomycin
|
DCZX7S7
|
Mitomycin
|
Lung adenocarcinoma (Cell Line: MDA-MB-231)
|
[3] |
|
Pomalidomide + Mitomycin
|
DC5OTGW
|
Mitomycin
|
Minimally invasive lung adenocarcinoma (Cell Line: NCI-H322M)
|
[3] |
|
Pomalidomide + Mitomycin
|
DCY0MX1
|
Mitomycin
|
Renal cell carcinoma (Cell Line: SN12C)
|
[3] |
|
Pomalidomide + Procarbazine
|
DCRDZTZ
|
Procarbazine
|
Chronic myelogenous leukemia (Cell Line: KBM-7)
|
[3] |
|
Pomalidomide + PF-02545920
|
DC2RZGG
|
PF-02545920
|
Chronic myelogenous leukemia (Cell Line: KBM-7)
|
[3] |
|
Pomalidomide + Etonogestrel
|
DCRMR19
|
Etonogestrel
|
Chronic myelogenous leukemia (Cell Line: KBM-7)
|
[3] |
|
Pomalidomide + Altretamine
|
DC1UKTS
|
Altretamine
|
Adenocarcinoma (Cell Line: OVCAR3)
|
[3] |
|
Pomalidomide + Altretamine
|
DCEK7ZL
|
Altretamine
|
Adenocarcinoma (Cell Line: A549)
|
[3] |
|
Pomalidomide + Altretamine
|
DC9BX6L
|
Altretamine
|
Adenocarcinoma (Cell Line: HCC-2998)
|
[3] |
|
Pomalidomide + Altretamine
|
DC0TQ62
|
Altretamine
|
Malignant melanoma (Cell Line: LOX IMVI)
|
[3] |
|
Pomalidomide + Fenoprofen
|
DCGBWIB
|
Fenoprofen
|
Chronic myelogenous leukemia (Cell Line: KBM-7)
|
[3] |
|
Pomalidomide + Idarubicin
|
DCGC3IS
|
Idarubicin
|
Glioblastoma? (Cell Line: T98G)
|
[3] |
|
Pomalidomide + Imatinib
|
DCE93H0
|
Imatinib
|
Chronic myelogenous leukemia (Cell Line: KBM-7)
|
[3] |
|
Pomalidomide + Darunavir
|
DC0L9R1
|
Darunavir
|
Chronic myelogenous leukemia (Cell Line: KBM-7)
|
[3] |
|
Pomalidomide + Methylene blue
|
DCZHSOV
|
Methylene blue
|
Chronic myelogenous leukemia (Cell Line: KBM-7)
|
[3] |
|
Pomalidomide + Chlorambucil
|
DC2AOS7
|
Chlorambucil
|
High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-8)
|
[3] |
|
Pomalidomide + Chlorambucil
|
DCKN8GK
|
Chlorambucil
|
Melanoma (Cell Line: UACC-257)
|
[3] |
|
Pomalidomide + Chlorambucil
|
DCA9P34
|
Chlorambucil
|
Papillary renal cell carcinoma (Cell Line: ACHN)
|
[3] |
|
Pomalidomide + Brincidofovir
|
DCMXSI0
|
Brincidofovir
|
Chronic myelogenous leukemia (Cell Line: KBM-7)
|
[3] |
|
Pomalidomide + ER819762
|
DC1MKXX
|
ER819762
|
Amelanotic melanoma (Cell Line: MDA-MB-435)
|
[3] |
|
Pomalidomide + Cisatracurium
|
DCH5D6M
|
Cisatracurium
|
Chronic myelogenous leukemia (Cell Line: KBM-7)
|
[3] |
|
Pomalidomide + Mefloquine
|
DCH4WUC
|
Mefloquine
|
Chronic myelogenous leukemia (Cell Line: KBM-7)
|
[3] |
|
Pomalidomide + Lacosamide
|
DCSVV1D
|
Lacosamide
|
Chronic myelogenous leukemia (Cell Line: KBM-7)
|
[3] |
|
Pomalidomide + Doxorubicin
|
DCSWMUO
|
Doxorubicin
|
Chronic myelogenous leukemia (Cell Line: KBM-7)
|
[3] |
|
Pomalidomide + Estramustine
|
DCMSIBV
|
Estramustine
|
Chronic myelogenous leukemia (Cell Line: KBM-7)
|
[3] |
|
Pomalidomide + Cerivastatin
|
DC7L3V2
|
Cerivastatin
|
Chronic myelogenous leukemia (Cell Line: KBM-7)
|
[3] |
|
Pomalidomide + Metaxalone
|
DCZZDD7
|
Metaxalone
|
Chronic myelogenous leukemia (Cell Line: KBM-7)
|
[3] |
|
Pomalidomide + Pentostatin
|
DCBWGAC
|
Pentostatin
|
Carcinoma (Cell Line: MCF7)
|
[5] |
|
Pomalidomide + Pentostatin
|
DCBG2H3
|
Pentostatin
|
Invasive ductal carcinoma (Cell Line: BT-549)
|
[5] |
|
Pomalidomide + Isoniazid
|
DCSINW6
|
Isoniazid
|
Invasive ductal carcinoma (Cell Line: HS 578T)
|
[5] |
|
Pomalidomide + Ifosfamide
|
DCMCMKM
|
Ifosfamide
|
Invasive ductal carcinoma (Cell Line: BT-549)
|
[5] |
|
Pomalidomide + Mitomycin
|
DC69JY5
|
Mitomycin
|
Carcinoma (Cell Line: MCF7)
|
[5] |
|
Pomalidomide + Mitomycin
|
DCDMXAF
|
Mitomycin
|
Colon adenocarcinoma (Cell Line: COLO 205)
|
[5] |
|
Pomalidomide + ER819762
|
DC2PY55
|
ER819762
|
Breast adenocarcinoma (Cell Line: MDA-MB-468)
|
[5] |
|
Pralatrexate + Pomalidomide
|
DC9Q5PO
|
Pralatrexate
|
Glioma (Cell Line: SF-295)
|
[3] |
|
Pralatrexate + Pomalidomide
|
DCGDKOE
|
Pralatrexate
|
Breast adenocarcinoma (Cell Line: MDA-MB-468)
|
[5] |
|
Pralatrexate + Pomalidomide
|
DCWCTPE
|
Pralatrexate
|
Lung adenocarcinoma (Cell Line: EKVX)
|
[4] |
|
Quinine + Pomalidomide
|
DCRHZR8
|
Quinine
|
Chronic myelogenous leukemia (Cell Line: KBM-7)
|
[3] |
|
Raloxifene + Pomalidomide
|
DC7OJBA
|
Raloxifene
|
Glioblastoma (Cell Line: SNB-75)
|
[3] |
|
Raloxifene + Pomalidomide
|
DCA9YHQ
|
Raloxifene
|
Plasma cell myeloma (Cell Line: RPMI-8226)
|
[3] |
|
Raloxifene + Pomalidomide
|
DCTL32V
|
Raloxifene
|
Renal cell carcinoma (Cell Line: SN12C)
|
[3] |
|
Raloxifene + Pomalidomide
|
DC43O9I
|
Raloxifene
|
Carcinoma (Cell Line: RXF 393)
|
[5] |
|
Raloxifene + Pomalidomide
|
DCE7BTT
|
Raloxifene
|
Invasive ductal carcinoma (Cell Line: HS 578T)
|
[5] |
|
Raloxifene + Pomalidomide
|
DCIAA8I
|
Raloxifene
|
Adenocarcinoma (Cell Line: NCIH23)
|
[4] |
|
Raloxifene + Pomalidomide
|
DCBV8LG
|
Raloxifene
|
Adenocarcinoma (Cell Line: SW-620)
|
[4] |
|
Raloxifene + Pomalidomide
|
DCUFA56
|
Raloxifene
|
Adenocarcinoma (Cell Line: HCT-15)
|
[4] |
|
Raloxifene + Pomalidomide
|
DC2JEWK
|
Raloxifene
|
Adenocarcinoma (Cell Line: HCC-2998)
|
[4] |
|
Raloxifene + Pomalidomide
|
DC9K3KL
|
Raloxifene
|
Amelanotic melanoma (Cell Line: M14)
|
[4] |
|
Raloxifene + Pomalidomide
|
DCGLUSG
|
Raloxifene
|
Cutaneous melanoma (Cell Line: SK-MEL-28)
|
[4] |
|
Raloxifene + Pomalidomide
|
DC62DGX
|
Raloxifene
|
High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-5)
|
[4] |
|
Raloxifene + Pomalidomide
|
DCU9DD4
|
Raloxifene
|
Large cell lung carcinoma (Cell Line: NCI-H460)
|
[4] |
|
Raloxifene + Pomalidomide
|
DCSJ0J0
|
Raloxifene
|
Lung adenocarcinoma (Cell Line: HOP-62)
|
[4] |
|
Raloxifene + Pomalidomide
|
DC9HAYX
|
Raloxifene
|
Lung adenocarcinoma (Cell Line: MDA-MB-231)
|
[4] |
|
Raloxifene + Pomalidomide
|
DC13ODB
|
Raloxifene
|
Malignant melanoma (Cell Line: UACC62)
|
[4] |
|
Raloxifene + Pomalidomide
|
DCMNOYL
|
Raloxifene
|
Malignant melanoma (Cell Line: LOX IMVI)
|
[4] |
|
Raloxifene + Pomalidomide
|
DCED0E0
|
Raloxifene
|
Melanoma (Cell Line: MALME-3M)
|
[4] |
|
Raloxifene + Pomalidomide
|
DCUBCMP
|
Raloxifene
|
Mixed endometrioid and clear cell carcinoma (Cell Line: IGROV1)
|
[4] |
|
Raloxifene + Pomalidomide
|
DCS8LI1
|
Raloxifene
|
Non-small cell lung carcinoma (Cell Line: HOP-92)
|
[4] |
|
Raloxifene + Pomalidomide
|
DCLGWKH
|
Raloxifene
|
Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3)
|
[4] |
|
Ruxolitinib + Pomalidomide
|
DCQENQW
|
Ruxolitinib
|
Astrocytoma (Cell Line: U251)
|
[3] |
|
Ruxolitinib + Pomalidomide
|
DCOTYOT
|
Ruxolitinib
|
Astrocytoma (Cell Line: SNB-19)
|
[3] |
|
Ruxolitinib + Pomalidomide
|
DCRZLRV
|
Ruxolitinib
|
Childhood T acute lymphoblastic leukemia (Cell Line: CCRF-CEM)
|
[3] |
|
Ruxolitinib + Pomalidomide
|
DC240CF
|
Ruxolitinib
|
Clear cell renal cell carcinoma (Cell Line: A498)
|
[3] |
|
Ruxolitinib + Pomalidomide
|
DCY9TYY
|
Ruxolitinib
|
Glioma (Cell Line: SF-539)
|
[3] |
|
Ruxolitinib + Pomalidomide
|
DCHD379
|
Ruxolitinib
|
Glioma (Cell Line: SF-268)
|
[3] |
|
Ruxolitinib + Pomalidomide
|
DCQU349
|
Ruxolitinib
|
Plasma cell myeloma (Cell Line: RPMI-8226)
|
[3] |
|
Ruxolitinib + Pomalidomide
|
DCO1LKK
|
Ruxolitinib
|
Colon adenocarcinoma (Cell Line: COLO 205)
|
[5] |
|
Ruxolitinib + Pomalidomide
|
DCIALVE
|
Ruxolitinib
|
Invasive ductal carcinoma (Cell Line: BT-549)
|
[5] |
|
Ruxolitinib + Pomalidomide
|
DCWTTGN
|
Ruxolitinib
|
Invasive ductal carcinoma (Cell Line: T-47D)
|
[5] |
|
Ruxolitinib + Pomalidomide
|
DCKXHS6
|
Ruxolitinib
|
Adenocarcinoma (Cell Line: DU-145)
|
[4] |
|
Ruxolitinib + Pomalidomide
|
DCWVBYU
|
Ruxolitinib
|
Adenocarcinoma (Cell Line: HCT-15)
|
[4] |
|
Ruxolitinib + Pomalidomide
|
DC40ZM2
|
Ruxolitinib
|
Amelanotic melanoma (Cell Line: MDA-MB-435)
|
[4] |
|
Ruxolitinib + Pomalidomide
|
DCF2KBJ
|
Ruxolitinib
|
High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-5)
|
[4] |
|
Ruxolitinib + Pomalidomide
|
DC7WGFT
|
Ruxolitinib
|
High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-4)
|
[4] |
|
Ruxolitinib + Pomalidomide
|
DCPQNQ7
|
Ruxolitinib
|
High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-8)
|
[4] |
|
Ruxolitinib + Pomalidomide
|
DCYUCJW
|
Ruxolitinib
|
High grade ovarian serous adenocarcinoma (Cell Line: NCI\\/ADR-RES)
|
[4] |
|
Ruxolitinib + Pomalidomide
|
DC20Q3N
|
Ruxolitinib
|
Large cell lung carcinoma (Cell Line: NCI-H460)
|
[4] |
|
Ruxolitinib + Pomalidomide
|
DC51DGW
|
Ruxolitinib
|
Lung adenocarcinoma (Cell Line: EKVX)
|
[4] |
|
Ruxolitinib + Pomalidomide
|
DC48IRL
|
Ruxolitinib
|
Lung adenocarcinoma (Cell Line: HOP-62)
|
[4] |
|
Ruxolitinib + Pomalidomide
|
DCKNCPZ
|
Ruxolitinib
|
Melanoma (Cell Line: SK-MEL-2)
|
[4] |
|
Ruxolitinib + Pomalidomide
|
DCC3E43
|
Ruxolitinib
|
Melanoma (Cell Line: MALME-3M)
|
[4] |
|
Ruxolitinib + Pomalidomide
|
DCOWHQB
|
Ruxolitinib
|
Non-small cell lung carcinoma (Cell Line: HOP-92)
|
[4] |
|
Ruxolitinib + Pomalidomide
|
DC37MAG
|
Ruxolitinib
|
Prostate carcinoma (Cell Line: PC-3)
|
[4] |
|
SCH 727965 + Pomalidomide
|
DCUVXGK
|
SCH 727965
|
Chronic myelogenous leukemia (Cell Line: KBM-7)
|
[3] |
|
SCH 727965 + Pomalidomide
|
DCUJ8PG
|
SCH 727965
|
Glioblastoma (Cell Line: SNB-75)
|
[3] |
|
SCH 727965 + Pomalidomide
|
DCRAJ9Q
|
SCH 727965
|
Plasma cell myeloma (Cell Line: RPMI-8226)
|
[3] |
|
SCH 727965 + Pomalidomide
|
DC7ZE5U
|
SCH 727965
|
Invasive ductal carcinoma (Cell Line: HS 578T)
|
[5] |
|
SCH 727965 + Pomalidomide
|
DC7QV99
|
SCH 727965
|
Adenocarcinoma (Cell Line: NCIH23)
|
[4] |
|
SCH 727965 + Pomalidomide
|
DCLUVUO
|
SCH 727965
|
Amelanotic melanoma (Cell Line: M14)
|
[4] |
|
Sirolimus + Pomalidomide
|
DCRUJ8J
|
Sirolimus
|
Malignant melanoma (Cell Line: UACC62)
|
[4] |
|
Sorafenib + Pomalidomide
|
DCC488L
|
Sorafenib
|
Adenocarcinoma (Cell Line: A549)
|
[3] |
|
Sorafenib + Pomalidomide
|
DCKC03S
|
Sorafenib
|
Adenocarcinoma (Cell Line: HT29)
|
[3] |
|
Sorafenib + Pomalidomide
|
DCAQ3ZT
|
Sorafenib
|
Adult acute myeloid leukemia (Cell Line: HL-60(TB))
|
[3] |
|
Sorafenib + Pomalidomide
|
DC11K7N
|
Sorafenib
|
Amelanotic melanoma (Cell Line: M14)
|
[3] |
|
Sorafenib + Pomalidomide
|
DC60TDJ
|
Sorafenib
|
Amelanotic melanoma (Cell Line: MDA-MB-435)
|
[3] |
|
Sorafenib + Pomalidomide
|
DCF2CZ8
|
Sorafenib
|
Glioblastoma (Cell Line: SNB-75)
|
[3] |
|
Sorafenib + Pomalidomide
|
DC8NNXY
|
Sorafenib
|
Lung adenocarcinoma (Cell Line: EKVX)
|
[3] |
|
Sorafenib + Pomalidomide
|
DCUB5Z4
|
Sorafenib
|
Lung adenocarcinoma (Cell Line: MDA-MB-231)
|
[3] |
|
Sorafenib + Pomalidomide
|
DCZILKF
|
Sorafenib
|
Melanoma (Cell Line: UACC-257)
|
[3] |
|
Sorafenib + Pomalidomide
|
DC47SGR
|
Sorafenib
|
Carcinoma (Cell Line: RXF 393)
|
[5] |
|
SY-1425 + Pomalidomide
|
DCOHKL2
|
SY-1425
|
Clear cell renal cell carcinoma (Cell Line: A498)
|
[3] |
|
SY-1425 + Pomalidomide
|
DCMNJGV
|
SY-1425
|
Renal cell carcinoma (Cell Line: UO-31)
|
[3] |
|
SY-1425 + Pomalidomide
|
DCCC91R
|
SY-1425
|
Adenocarcinoma (Cell Line: HCT116)
|
[4] |
|
SY-1425 + Pomalidomide
|
DC1OP75
|
SY-1425
|
Non-small cell lung carcinoma (Cell Line: HOP-92)
|
[4] |
|
Taxol + Pomalidomide
|
DC29MCU
|
Taxol
|
Clear cell renal cell carcinoma (Cell Line: TK-10)
|
[3] |
|
Taxol + Pomalidomide
|
DC6KFW5
|
Taxol
|
Colon adenocarcinoma (Cell Line: COLO 205)
|
[5] |
|
Taxol + Pomalidomide
|
DCP54G9
|
Taxol
|
Adenocarcinoma (Cell Line: HCT116)
|
[4] |
|
TEM + Pomalidomide
|
DCOYA3Y
|
TEM
|
Chronic myelogenous leukemia (Cell Line: K-562)
|
[3] |
|
TEM + Pomalidomide
|
DCB8U5C
|
TEM
|
Colon adenocarcinoma (Cell Line: COLO 205)
|
[5] |
|
TEM + Pomalidomide
|
DC99ZQN
|
TEM
|
Adenocarcinoma (Cell Line: OVCAR3)
|
[4] |
|
TEM + Pomalidomide
|
DCDBUBK
|
TEM
|
Adenocarcinoma (Cell Line: HCT116)
|
[4] |
|
TEM + Pomalidomide
|
DCKYQFV
|
TEM
|
Melanoma (Cell Line: UACC-257)
|
[4] |
|
TEM + Pomalidomide
|
DCSTNZZ
|
TEM
|
Minimally invasive lung adenocarcinoma (Cell Line: NCI-H322M)
|
[4] |
|
Terameprocol + Pomalidomide
|
DC5D3RS
|
Terameprocol
|
Adult acute myeloid leukemia (Cell Line: HL-60(TB))
|
[3] |
|
Terameprocol + Pomalidomide
|
DC6196F
|
Terameprocol
|
Chronic myelogenous leukemia (Cell Line: KBM-7)
|
[3] |
|
Terameprocol + Pomalidomide
|
DCM8X5L
|
Terameprocol
|
Glioma (Cell Line: SF-295)
|
[3] |
|
Terameprocol + Pomalidomide
|
DCU5FW8
|
Terameprocol
|
Plasma cell myeloma (Cell Line: RPMI-8226)
|
[3] |
|
Terameprocol + Pomalidomide
|
DC0GZB5
|
Terameprocol
|
Breast adenocarcinoma (Cell Line: MDA-MB-468)
|
[5] |
|
Terameprocol + Pomalidomide
|
DCN9GNV
|
Terameprocol
|
Colon adenocarcinoma (Cell Line: COLO 205)
|
[5] |
|
Terameprocol + Pomalidomide
|
DC7R7YH
|
Terameprocol
|
Invasive ductal carcinoma (Cell Line: HS 578T)
|
[5] |
|
Terameprocol + Pomalidomide
|
DC0DKCT
|
Terameprocol
|
Adenocarcinoma (Cell Line: OVCAR3)
|
[4] |
|
Terameprocol + Pomalidomide
|
DCPC80A
|
Terameprocol
|
Adenocarcinoma (Cell Line: HCT116)
|
[4] |
|
Terameprocol + Pomalidomide
|
DCFQ23H
|
Terameprocol
|
Adenocarcinoma (Cell Line: HT29)
|
[4] |
|
Terameprocol + Pomalidomide
|
DCI7CN6
|
Terameprocol
|
Adenocarcinoma (Cell Line: HCC-2998)
|
[4] |
|
Terameprocol + Pomalidomide
|
DCT3L6S
|
Terameprocol
|
Cutaneous melanoma (Cell Line: SK-MEL-5)
|
[4] |
|
Terameprocol + Pomalidomide
|
DCARGR9
|
Terameprocol
|
High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-5)
|
[4] |
|
Terameprocol + Pomalidomide
|
DCFK5YD
|
Terameprocol
|
Large cell lung carcinoma (Cell Line: NCI-H460)
|
[4] |
|
Terameprocol + Pomalidomide
|
DC5U30V
|
Terameprocol
|
Lung adenocarcinoma (Cell Line: EKVX)
|
[4] |
|
Terameprocol + Pomalidomide
|
DCXAG8C
|
Terameprocol
|
Malignant melanoma (Cell Line: UACC62)
|
[4] |
|
Terameprocol + Pomalidomide
|
DCXZXCR
|
Terameprocol
|
Melanoma (Cell Line: MALME-3M)
|
[4] |
|
Terameprocol + Pomalidomide
|
DCQZO27
|
Terameprocol
|
Minimally invasive lung adenocarcinoma (Cell Line: NCI-H322M)
|
[4] |
|
Terameprocol + Pomalidomide
|
DCBA0QB
|
Terameprocol
|
Mixed endometrioid and clear cell carcinoma (Cell Line: IGROV1)
|
[4] |
|
Testosterone + Pomalidomide
|
DCR1BH2
|
Testosterone
|
Chronic myelogenous leukemia (Cell Line: KBM-7)
|
[3] |
|
Thioguanine + Pomalidomide
|
DC2BJHM
|
Thioguanine
|
Clear cell renal cell carcinoma (Cell Line: CAKI-1)
|
[3] |
|
Thioguanine + Pomalidomide
|
DC9MLLQ
|
Thioguanine
|
Glioma (Cell Line: SF-295)
|
[3] |
|
Thioguanine + Pomalidomide
|
DCSTFUH
|
Thioguanine
|
Renal cell carcinoma (Cell Line: SN12C)
|
[3] |
|
Thioguanine + Pomalidomide
|
DC7LYF1
|
Thioguanine
|
Breast adenocarcinoma (Cell Line: MDA-MB-468)
|
[5] |
|
Thioguanine + Pomalidomide
|
DCD65N0
|
Thioguanine
|
Colon carcinoma (Cell Line: KM12)
|
[5] |
|
Thioguanine + Pomalidomide
|
DC8JQT4
|
Thioguanine
|
Adenocarcinoma (Cell Line: HCT116)
|
[4] |
|
Thioguanine + Pomalidomide
|
DC4R8AJ
|
Thioguanine
|
High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-4)
|
[4] |
|
Thioguanine + Pomalidomide
|
DCRFQ2P
|
Thioguanine
|
Lung adenocarcinoma (Cell Line: EKVX)
|
[4] |
|
Thioguanine + Pomalidomide
|
DCHZ699
|
Thioguanine
|
Malignant melanoma (Cell Line: UACC62)
|
[4] |
|
Thioguanine + Pomalidomide
|
DC4N13L
|
Thioguanine
|
Non-small cell lung carcinoma (Cell Line: HOP-92)
|
[4] |
|
Topotecan + Pomalidomide
|
DC4KCIJ
|
Topotecan
|
Breast adenocarcinoma (Cell Line: MDA-MB-468)
|
[5] |
|
Topotecan + Pomalidomide
|
DCWKEGY
|
Topotecan
|
Carcinoma (Cell Line: MCF7)
|
[5] |
|
Topotecan + Pomalidomide
|
DCN1R4Y
|
Topotecan
|
Amelanotic melanoma (Cell Line: MDA-MB-435)
|
[4] |
|
Topotecan + Pomalidomide
|
DCHHIVH
|
Topotecan
|
Clear cell renal cell carcinoma (Cell Line: CAKI-1)
|
[4] |
|
Topotecan + Pomalidomide
|
DCRFHGF
|
Topotecan
|
Cutaneous melanoma (Cell Line: SK-MEL-28)
|
[4] |
|
Topotecan + Pomalidomide
|
DCMT127
|
Topotecan
|
Glioblastoma (Cell Line: SNB-75)
|
[4] |
|
Topotecan + Pomalidomide
|
DC6R49Q
|
Topotecan
|
Glioma (Cell Line: SF-268)
|
[4] |
|
Topotecan + Pomalidomide
|
DCE3HMW
|
Topotecan
|
Glioma (Cell Line: SF-295)
|
[4] |
|
Topotecan + Pomalidomide
|
DCUTGBS
|
Topotecan
|
Lung adenocarcinoma (Cell Line: EKVX)
|
[4] |
|
Topotecan + Pomalidomide
|
DCOS4WV
|
Topotecan
|
Minimally invasive lung adenocarcinoma (Cell Line: NCI-H322M)
|
[4] |
|
Topotecan + Pomalidomide
|
DCQFJWY
|
Topotecan
|
Mixed endometrioid and clear cell carcinoma (Cell Line: IGROV1)
|
[4] |
|
Topotecan + Pomalidomide
|
DC7EW3X
|
Topotecan
|
Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3)
|
[4] |
|
Topotecan + Pomalidomide
|
DC6OD2X
|
Topotecan
|
Pleural epithelioid mesothelioma (Cell Line: NCI-H226)
|
[4] |
|
Topotecan + Pomalidomide
|
DCMHXOD
|
Topotecan
|
Prostate carcinoma (Cell Line: PC-3)
|
[4] |
|
Topotecan + Pomalidomide
|
DC17JQL
|
Topotecan
|
Renal cell carcinoma (Cell Line: SN12C)
|
[4] |
|
Triapine + Pomalidomide
|
DCX6ZT8
|
Triapine
|
Invasive ductal carcinoma (Cell Line: T-47D)
|
[5] |
|
Triapine + Pomalidomide
|
DCG056I
|
Triapine
|
Astrocytoma (Cell Line: U251)
|
[4] |
|
Triapine + Pomalidomide
|
DC21ZO9
|
Triapine
|
Large cell lung carcinoma (Cell Line: NCI-H460)
|
[4] |
|
Trifluridine + Pomalidomide
|
DCRX58I
|
Trifluridine
|
Adult acute myeloid leukemia (Cell Line: HL-60(TB))
|
[3] |
|
Trifluridine + Pomalidomide
|
DCTPR02
|
Trifluridine
|
Adenocarcinoma (Cell Line: SW-620)
|
[4] |
|
Uracil mustard + Pomalidomide
|
DC2DEA8
|
Uracil mustard
|
Glioma (Cell Line: SF-295)
|
[3] |
|
Uracil mustard + Pomalidomide
|
DCQGJCG
|
Uracil mustard
|
High grade ovarian serous adenocarcinoma (Cell Line: NCI\\/ADR-RES)
|
[4] |
|
Valrubicin + Pomalidomide
|
DCV1Z5J
|
Valrubicin
|
Clear cell renal cell carcinoma (Cell Line: TK-10)
|
[3] |
|
Valrubicin + Pomalidomide
|
DCP6XU7
|
Valrubicin
|
Carcinoma (Cell Line: RXF 393)
|
[5] |
|
Vandetanib + Pomalidomide
|
DCW2YWH
|
Vandetanib
|
Colon carcinoma (Cell Line: KM12)
|
[5] |
|
Vandetanib + Pomalidomide
|
DC383PG
|
Vandetanib
|
Invasive ductal carcinoma (Cell Line: HS 578T)
|
[5] |
|
Vandetanib + Pomalidomide
|
DCHPB47
|
Vandetanib
|
Invasive ductal carcinoma (Cell Line: T-47D)
|
[5] |
|
Vandetanib + Pomalidomide
|
DCIJZTA
|
Vandetanib
|
Invasive ductal carcinoma (Cell Line: BT-549)
|
[5] |
|
Vandetanib + Pomalidomide
|
DCUSRBL
|
Vandetanib
|
Adenocarcinoma (Cell Line: HCC-2998)
|
[4] |
|
Vandetanib + Pomalidomide
|
DCEHVLW
|
Vandetanib
|
Adult acute myeloid leukemia (Cell Line: HL-60(TB))
|
[4] |
|
Vandetanib + Pomalidomide
|
DCJAZMC
|
Vandetanib
|
Amelanotic melanoma (Cell Line: MDA-MB-435)
|
[4] |
|
Vandetanib + Pomalidomide
|
DCFPZUE
|
Vandetanib
|
Amelanotic melanoma (Cell Line: M14)
|
[4] |
|
Vandetanib + Pomalidomide
|
DCQ2KES
|
Vandetanib
|
Astrocytoma (Cell Line: SNB-19)
|
[4] |
|
Vandetanib + Pomalidomide
|
DCGGN3O
|
Vandetanib
|
Cutaneous melanoma (Cell Line: SK-MEL-5)
|
[4] |
|
Vandetanib + Pomalidomide
|
DCA3M3C
|
Vandetanib
|
Cutaneous melanoma (Cell Line: SK-MEL-28)
|
[4] |
|
Vandetanib + Pomalidomide
|
DCITFJ3
|
Vandetanib
|
Glioma (Cell Line: SF-268)
|
[4] |
|
Vandetanib + Pomalidomide
|
DCUUHTW
|
Vandetanib
|
High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-8)
|
[4] |
|
Vandetanib + Pomalidomide
|
DC6OCS1
|
Vandetanib
|
Melanoma (Cell Line: SK-MEL-2)
|
[4] |
|
Vandetanib + Pomalidomide
|
DCVVVFV
|
Vandetanib
|
Plasma cell myeloma (Cell Line: RPMI-8226)
|
[4] |
|
Vandetanib + Pomalidomide
|
DCXIN86
|
Vandetanib
|
Prostate carcinoma (Cell Line: PC-3)
|
[4] |
|
Vemurafenib + Pomalidomide
|
DCDBP0B
|
Vemurafenib
|
Carcinoma (Cell Line: RXF 393)
|
[5] |
|
Vemurafenib + Pomalidomide
|
DCVCX4I
|
Vemurafenib
|
Carcinoma (Cell Line: MCF7)
|
[5] |
|
Vemurafenib + Pomalidomide
|
DCZSQYQ
|
Vemurafenib
|
Colon carcinoma (Cell Line: KM12)
|
[5] |
|
Vemurafenib + Pomalidomide
|
DCI4BRB
|
Vemurafenib
|
Invasive ductal carcinoma (Cell Line: BT-549)
|
[5] |
|
Vemurafenib + Pomalidomide
|
DCG73CU
|
Vemurafenib
|
Adenocarcinoma (Cell Line: DU-145)
|
[4] |
|
Vemurafenib + Pomalidomide
|
DC3XDZ7
|
Vemurafenib
|
Adenocarcinoma (Cell Line: OVCAR3)
|
[4] |
|
Vemurafenib + Pomalidomide
|
DCTMQ91
|
Vemurafenib
|
Adenocarcinoma (Cell Line: NCIH23)
|
[4] |
|
Vemurafenib + Pomalidomide
|
DCWVDGI
|
Vemurafenib
|
Adenocarcinoma (Cell Line: HCT-15)
|
[4] |
|
Vemurafenib + Pomalidomide
|
DCXRMWK
|
Vemurafenib
|
Adenocarcinoma (Cell Line: HCT116)
|
[4] |
|
Vemurafenib + Pomalidomide
|
DCB3R6H
|
Vemurafenib
|
Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4)
|
[4] |
|
Vemurafenib + Pomalidomide
|
DC3BOXK
|
Vemurafenib
|
Astrocytoma (Cell Line: SNB-19)
|
[4] |
|
Vemurafenib + Pomalidomide
|
DCIXGNL
|
Vemurafenib
|
Childhood T acute lymphoblastic leukemia (Cell Line: CCRF-CEM)
|
[4] |
|
Vemurafenib + Pomalidomide
|
DCRP6LU
|
Vemurafenib
|
Chronic myelogenous leukemia (Cell Line: K-562)
|
[4] |
|
Vemurafenib + Pomalidomide
|
DCU22AG
|
Vemurafenib
|
Clear cell renal cell carcinoma (Cell Line: 786-0)
|
[4] |
|
Vemurafenib + Pomalidomide
|
DCTD85S
|
Vemurafenib
|
Glioblastoma (Cell Line: SNB-75)
|
[4] |
|
Vemurafenib + Pomalidomide
|
DC1YQQI
|
Vemurafenib
|
Glioma (Cell Line: SF-268)
|
[4] |
|
Vemurafenib + Pomalidomide
|
DC8VCNR
|
Vemurafenib
|
High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-4)
|
[4] |
|
Vemurafenib + Pomalidomide
|
DCE64Q2
|
Vemurafenib
|
High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-8)
|
[4] |
|
Vemurafenib + Pomalidomide
|
DCE8GQX
|
Vemurafenib
|
High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-5)
|
[4] |
|
Vemurafenib + Pomalidomide
|
DCDWLTZ
|
Vemurafenib
|
High grade ovarian serous adenocarcinoma (Cell Line: NCI\\/ADR-RES)
|
[4] |
|
Vemurafenib + Pomalidomide
|
DCX7V7X
|
Vemurafenib
|
Lung adenocarcinoma (Cell Line: EKVX)
|
[4] |
|
Vemurafenib + Pomalidomide
|
DCGFLBX
|
Vemurafenib
|
Lung adenocarcinoma (Cell Line: MDA-MB-231)
|
[4] |
|
Vemurafenib + Pomalidomide
|
DCNC9XE
|
Vemurafenib
|
Lung adenocarcinoma (Cell Line: NCI-H522)
|
[4] |
|
Vemurafenib + Pomalidomide
|
DCSDY3C
|
Vemurafenib
|
Melanoma (Cell Line: SK-MEL-2)
|
[4] |
|
Vemurafenib + Pomalidomide
|
DCRMPQF
|
Vemurafenib
|
Minimally invasive lung adenocarcinoma (Cell Line: NCI-H322M)
|
[4] |
|
Vemurafenib + Pomalidomide
|
DC1BPA8
|
Vemurafenib
|
Non-small cell lung carcinoma (Cell Line: HOP-92)
|
[4] |
|
Vemurafenib + Pomalidomide
|
DC4H6K9
|
Vemurafenib
|
Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3)
|
[4] |
|
Vemurafenib + Pomalidomide
|
DC2G4KX
|
Vemurafenib
|
Renal cell carcinoma (Cell Line: SN12C)
|
[4] |
|
Vinflunine + Pomalidomide
|
DCQY8BD
|
Vinflunine
|
Astrocytoma (Cell Line: U251)
|
[3] |
|
Vinflunine + Pomalidomide
|
DC6E56E
|
Vinflunine
|
Glioma (Cell Line: SF-539)
|
[3] |
|
Vinflunine + Pomalidomide
|
DC9ICHN
|
Vinflunine
|
Plasma cell myeloma (Cell Line: RPMI-8226)
|
[3] |
|
Vinflunine + Pomalidomide
|
DC59YGW
|
Vinflunine
|
Breast adenocarcinoma (Cell Line: MDA-MB-468)
|
[5] |
|
Vinflunine + Pomalidomide
|
DCB1WC5
|
Vinflunine
|
Invasive ductal carcinoma (Cell Line: T-47D)
|
[5] |
|
Vinflunine + Pomalidomide
|
DCQTDWI
|
Vinflunine
|
Invasive ductal carcinoma (Cell Line: HS 578T)
|
[5] |
|
Vinflunine + Pomalidomide
|
DCIAW2K
|
Vinflunine
|
Adenocarcinoma (Cell Line: HCC-2998)
|
[4] |
|
Vinflunine + Pomalidomide
|
DCL5ZAZ
|
Vinflunine
|
Amelanotic melanoma (Cell Line: M14)
|
[4] |
|
Vinflunine + Pomalidomide
|
DCE44I5
|
Vinflunine
|
Lung adenocarcinoma (Cell Line: HOP-62)
|
[4] |
|
Vinflunine + Pomalidomide
|
DCO7LGR
|
Vinflunine
|
Malignant melanoma (Cell Line: UACC62)
|
[4] |
|
Vinflunine + Pomalidomide
|
DCTSLWZ
|
Vinflunine
|
Minimally invasive lung adenocarcinoma (Cell Line: NCI-H322M)
|
[4] |
|
Vismodegib + Pomalidomide
|
DCO7MTB
|
Vismodegib
|
Carcinoma (Cell Line: MCF7)
|
[5] |
|
Vismodegib + Pomalidomide
|
DCXR1TS
|
Vismodegib
|
Invasive ductal carcinoma (Cell Line: HS 578T)
|
[5] |
|
Vismodegib + Pomalidomide
|
DC9G3X7
|
Vismodegib
|
Invasive ductal carcinoma (Cell Line: BT-549)
|
[5] |
|
Vismodegib + Pomalidomide
|
DCVTCLO
|
Vismodegib
|
Adenocarcinoma (Cell Line: DU-145)
|
[4] |
|
Vismodegib + Pomalidomide
|
DCN5MRE
|
Vismodegib
|
Adenocarcinoma (Cell Line: HCC-2998)
|
[4] |
|
Vismodegib + Pomalidomide
|
DCFNTZB
|
Vismodegib
|
Adult acute myeloid leukemia (Cell Line: HL-60(TB))
|
[4] |
|
Vismodegib + Pomalidomide
|
DCEV29H
|
Vismodegib
|
Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4)
|
[4] |
|
Vismodegib + Pomalidomide
|
DCK7LN7
|
Vismodegib
|
Amelanotic melanoma (Cell Line: MDA-MB-435)
|
[4] |
|
Vismodegib + Pomalidomide
|
DCAXEVF
|
Vismodegib
|
Amelanotic melanoma (Cell Line: M14)
|
[4] |
|
Vismodegib + Pomalidomide
|
DC54E06
|
Vismodegib
|
Astrocytoma (Cell Line: U251)
|
[4] |
|
Vismodegib + Pomalidomide
|
DCWGK0V
|
Vismodegib
|
Astrocytoma (Cell Line: SNB-19)
|
[4] |
|
Vismodegib + Pomalidomide
|
DCZJHTE
|
Vismodegib
|
Childhood T acute lymphoblastic leukemia (Cell Line: CCRF-CEM)
|
[4] |
|
Vismodegib + Pomalidomide
|
DCBVLX5
|
Vismodegib
|
Chronic myelogenous leukemia (Cell Line: K-562)
|
[4] |
|
Vismodegib + Pomalidomide
|
DC7PIKD
|
Vismodegib
|
Clear cell renal cell carcinoma (Cell Line: A498)
|
[4] |
|
Vismodegib + Pomalidomide
|
DCXKNXP
|
Vismodegib
|
Clear cell renal cell carcinoma (Cell Line: 786-0)
|
[4] |
|
Vismodegib + Pomalidomide
|
DCTOH9O
|
Vismodegib
|
Cutaneous melanoma (Cell Line: SK-MEL-28)
|
[4] |
|
Vismodegib + Pomalidomide
|
DCFLVNZ
|
Vismodegib
|
Glioblastoma (Cell Line: SNB-75)
|
[4] |
|
Vismodegib + Pomalidomide
|
DCOLHQ3
|
Vismodegib
|
Glioma (Cell Line: SF-539)
|
[4] |
|
Vismodegib + Pomalidomide
|
DC782Y7
|
Vismodegib
|
Glioma (Cell Line: SF-268)
|
[4] |
|
Vismodegib + Pomalidomide
|
DC3IA4I
|
Vismodegib
|
High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-4)
|
[4] |
|
Vismodegib + Pomalidomide
|
DCW3Z9Z
|
Vismodegib
|
High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-8)
|
[4] |
|
Vismodegib + Pomalidomide
|
DCEEOZN
|
Vismodegib
|
High grade ovarian serous adenocarcinoma (Cell Line: NCI\\/ADR-RES)
|
[4] |
|
Vismodegib + Pomalidomide
|
DCS08D3
|
Vismodegib
|
Melanoma (Cell Line: SK-MEL-2)
|
[4] |
|
Vismodegib + Pomalidomide
|
DC6MH2X
|
Vismodegib
|
Melanoma (Cell Line: UACC-257)
|
[4] |
|
Vismodegib + Pomalidomide
|
DC55O9K
|
Vismodegib
|
Minimally invasive lung adenocarcinoma (Cell Line: NCI-H322M)
|
[4] |
|
Vismodegib + Pomalidomide
|
DC3I1US
|
Vismodegib
|
Non-small cell lung carcinoma (Cell Line: HOP-92)
|
[4] |
|
Vismodegib + Pomalidomide
|
DCYINTX
|
Vismodegib
|
Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3)
|
[4] |
|
Vismodegib + Pomalidomide
|
DCFM1J3
|
Vismodegib
|
Papillary renal cell carcinoma (Cell Line: ACHN)
|
[4] |
|
Vismodegib + Pomalidomide
|
DC39JDZ
|
Vismodegib
|
Plasma cell myeloma (Cell Line: RPMI-8226)
|
[4] |
|
Vismodegib + Pomalidomide
|
DCAYIT3
|
Vismodegib
|
Pleural epithelioid mesothelioma (Cell Line: NCI-H226)
|
[4] |
| ------------------------------------------------------------------------------------ |
|
|
|
|
